recent publications

• academic article

  • Berger, J. S., Bhatt, D. L., Steg, P. G., Steinhubl, S. R., Montalescot, G., Shao, M. Y., Hacke, W., Fox, K. A., Berger, P. B., Topol, E. J., Lincoff, A. M., Investigators, Charisma Bleeding, mortality, and antiplatelet therapy: Results from the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (charisma) trial American Heart Journal  2011 162:98-105  DOI:10.1016/j.ahj.2011.04.015  PMID:21742095
  • Berger, J. S., Bhatt, D. L., Steinhubl, S. R., Shao, M. Y., Steg, P. G., Montalescot, G., Hacke, W., Fox, K. A., Lincoff, A. M., Topol, E. J., Berger, P. B., Investigators, Charisma Smoking, clopidogrel, and mortality in patients with established cardiovascular disease Circulation  2009 120:2337-2344  DOI:10.1161/circulationaha.109.866533  PMID:19933933  PMCID:PMC2814172
  • Bhatt, D. L., Fox, K. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., Flather, M. D., Haffner, S. M., et al. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial American Heart Journal  2005 150:401.e1-401.e7  DOI:10.1016/j.ahj.2005.03.017  PMID:16169314